The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.

scientific article published on 11 April 2016

The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1182/BLOOD-2016-01-688796
P932PMC publication ID4920022
P698PubMed publication ID27069256

P50authorAndrew W. RobertsQ43445505
Constantine S. TamQ55445006
David C HuangQ56987660
Joshua FeinQ57117994
Ian J MajewskiQ62263878
Mary Ann AndersonQ82872506
Anthony LetaiQ88032748
P2093author name stringJohn F Seymour
Jennifer R Brown
Matthew S Davids
Su Young Kim
Jing Deng
David Segal
Lijian Yu
David Westerman
Sari L Heitner Enschede
Eric G Si
P2860cites workThe Hallmarks of CancerQ221226
Hallmarks of Cancer: The Next GenerationQ22252312
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family membersQ24337108
miR-15 and miR-16 induce apoptosis by targeting BCL2Q24536069
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelinesQ24616084
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2Q27642888
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsQ27683708
TP53 mutation and survival in chronic lymphocytic leukemiaQ27851577
p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxaQ28204059
Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacityQ28268312
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemiaQ28394721
Tumor spectrum analysis in p53-mutant miceQ29617436
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemiaQ29620690
Clearance of apoptotic cells: implications in health and diseaseQ30433781
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory diseaseQ33398808
Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199.Q33412553
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic LeukemiaQ34504188
Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.Q35250940
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinibQ35450520
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapyQ35761070
Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic LeukemiaQ35958056
Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemiaQ36352532
Evolution and impact of subclonal mutations in chronic lymphocytic leukemiaQ36619124
Targeting the B-cell lymphoma/leukemia 2 family in cancerQ38014808
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy.Q38172752
Targeting BCL2 for the treatment of lymphoid malignanciesQ38232485
Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells.Q38791801
An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivoQ38904501
A unified model of mammalian BCL-2 protein family interactions at the mitochondria.Q39292731
Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcomeQ41223060
Genetic analysis of chemoresistance in primary murine lymphomas.Q43422059
The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia.Q45916401
ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets.Q50858312
DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2Q57338694
P433issue25
P407language of work or nameEnglishQ1860
P921main subjectpatientQ181600
apoptotic processQ14599311
P304page(s)3215-3224
P577publication date2016-04-11
P1433published inBloodQ885070
P1476titleThe BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism
P478volume127

Reverse relations

cites work (P2860)
Q64120024A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy
Q60480019ABT-199 (Venetoclax), a BH3-mimetic Bcl-2 inhibitor, does not cause Ca2+ -signalling dysregulation or toxicity in pancreatic acinar cells
Q39227773Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia
Q50074012Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies
Q90425403BCL-2 inhibition in AML: an unexpected bonus?
Q91992641BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models
Q37588301Biguanides sensitize leukemia cells to ABT-737-induced apoptosis by inhibiting mitochondrial electron transport
Q93376413Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas
Q39006397Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia
Q53699332Delineation of the androgen-regulated signaling pathways in prostate cancer facilitates the development of novel therapeutic approaches.
Q37702281Development of venetoclax for therapy of lymphoid malignancies.
Q39027800Diffuse large B-cell lymphoma: R-CHOP failure-what to do?
Q56811078Discovery of Mcl-1 inhibitors from integrated high throughput and virtual screening
Q100750110Downregulation of PUMA underlies resistance to FGFR1 inhibitors in the stem cell leukemia/lymphoma syndrome
Q93223071Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma
Q51737093Emerging molecular mechanisms in chemotherapy: Ca2+ signaling at the mitochondria-associated endoplasmic reticulum membranes.
Q47670541Emerging molecular predictive and prognostic factors in acute myeloid leukemia
Q91994349Emerging treatment options for patients with p53-pathway-deficient CLL
Q61454350Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells
Q37209768High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells
Q37587294How to unleash mitochondrial apoptotic blockades to kill cancers?
Q38904537Integrating functional genomics to accelerate mechanistic personalized medicine
Q38943877Magic pills: new oral drugs to treat chronic lymphocytic leukemia.
Q49692075Management of high risk chronic lymphocytic leukaemia (CLL) patients in Australia
Q52582842Microenvironment-induced PIM kinases promote CXCR4-triggered mTOR pathway required for chronic lymphocytic leukaemia cell migration.
Q28069552Mitochondrial apoptosis and BH3 mimetics
Q38636162Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.
Q58602178NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death
Q47661789Paclitaxel Reduces Axonal Bclw to Initiate IP3R1-Dependent Axon Degeneration
Q51160342Pathways and mechanisms of venetoclax resistance.
Q38818283Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.
Q33438494Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Q91474390Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma
Q38997367Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia
Q40041785Regulation of Apoptosis during Flavivirus Infection
Q90399550Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies
Q55379234Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile.
Q50906605TP53 in adult acute lymphoblastic leukemia.
Q38982682Targeted Therapy in Chronic Lymphocytic Leukemia (CLL).
Q38738661Targeted therapy in the treatment of chronic lymphocytic leukemia: facts, shortcomings and hopes for the future
Q39456786Targeting BCL-2-like Proteins to Kill Cancer Cells
Q38996888Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies
Q90747788Targeting Bcl-2 for the treatment of multiple myeloma
Q90047057Targeting Mitochondrial Apoptosis to Overcome Treatment Resistance in Cancer
Q55017371Targeting Mitochondrial Bioenergetics as a Therapeutic Strategy for Chronic Lymphocytic Leukemia.
Q92951967Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide
Q47166330The BCL-2 arbiters of apoptosis and their growing role as cancer targets
Q38766548The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia
Q89493561The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
Q42371592The genetically engineered drug rhCNB induces apoptosis via a mitochondrial route in tumor cells
Q49989104The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment
Q51014811The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia.
Q38798849To Prime, or Not to Prime: That Is the Question
Q64904346Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL.
Q59333353VDAC2 enables BAX to mediate apoptosis and limit tumor development
Q90071201Venetoclax for the Treatment of Chronic Lymphocytic Leukemia
Q47875923Venetoclax for the treatment of chronic lymphocytic leukemia.
Q38685358Venetoclax for the treatment of patients with chronic lymphocytic leukemia
Q64074946Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement
Q33433407Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.
Q90203333Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia
Q47159040Why do BCL-2 inhibitors work and where should we use them in the clinic?
Q37678946miR-125b-5p enhances chemotherapy sensitivity to cisplatin by down-regulating Bcl2 in gallbladder cancer

Search more.